Skip to main content
Erschienen in:
Buchtitelbild

2015 | OriginalPaper | Buchkapitel

Functional Analysis of microRNA in Multiple Myeloma

verfasst von : Maria Teresa Di Martino, Ph.D., Nicola Amodio, Pierfrancesco Tassone, M.D., Pierosandro Tagliaferri

Verlag: Springer New York

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

MicroRNAs (miRNAs) are short non coding RNAs that regulate the gene expression and play a relevant role in physiopathological mechanisms such as development, proliferation, death, and differentiation of normal and cancer cells. Recently, abnormal expression of miRNAs has been reported in most of solid or hematopoietic malignancies, including multiple myeloma (MM), where miRNAs have been found deeply dysregulated and act as oncogenes or tumor suppressors. Presently, the most recognized approach for definition of miRNA portraits is based on microarray profiling analysis. We here describe a workflow based on the identification of dysregulated miRNAs in plasma cells from MM patients based on Affymetrix technology. We describe how it is possible to search miRNA putative targets performing whole gene expression profile on MM cell lines transfected with miRNA mimics or inhibitors followed by luciferase reporter assay to analyze the specific targeting of the 3′untranslated region (UTR) sequence of a mRNA by selected miRNAs. These technological approaches are suitable strategies for the identification of relevant druggable targets in MM.
Literatur
2.
3.
Zurück zum Zitat Tassone P, Tagliaferri P (2012) Editorial: new approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). Curr Cancer Drug Targets 12:741–742CrossRefPubMed Tassone P, Tagliaferri P (2012) Editorial: new approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). Curr Cancer Drug Targets 12:741–742CrossRefPubMed
4.
Zurück zum Zitat Rossi M et al (2013) From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets 14:1144–1149CrossRefPubMed Rossi M et al (2013) From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets 14:1144–1149CrossRefPubMed
5.
Zurück zum Zitat Rossi M et al (2014) MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol 15:459–467CrossRefPubMed Rossi M et al (2014) MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol 15:459–467CrossRefPubMed
9.
Zurück zum Zitat Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A (2012) MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 12:823–837CrossRefPubMed Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A (2012) MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 12:823–837CrossRefPubMed
12.
17.
18.
Zurück zum Zitat Rossi M et al (2013) miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 228:1506–1515. doi:10.1002/jcp.24306 CrossRefPubMed Rossi M et al (2013) miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 228:1506–1515. doi:10.​1002/​jcp.​24306 CrossRefPubMed
22.
Metadaten
Titel
Functional Analysis of microRNA in Multiple Myeloma
verfasst von
Maria Teresa Di Martino, Ph.D.
Nicola Amodio
Pierfrancesco Tassone, M.D.
Pierosandro Tagliaferri
Copyright-Jahr
2015
Verlag
Springer New York
DOI
https://doi.org/10.1007/7651_2015_250